UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Compugen is implementing good security practices.
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big pharmas such as Novaris AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010 decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.
This report shows a preliminary security rating for Compugen. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.Get a deeper scan →
Read more about the latest issues in cybersecurity
The Vendor Security Alliance (VSA) questionnaire was created by a coalition of companies committed ...
A man-in-the-middle attack (MITM attack) is a cyber attack where an attacker relays and possibly ...
Compare Compugen's security performance with other companies